MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 46 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.
David M. O’Malley, Kathleen N. Moore, Ignace Vergote, Lainie P. Martin, Lucy Gilbert, Antonio González-Martı́n +4 more
2017· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
14
citations
affno abstractunlabeled
Dose Density by Any Other Name
William M. Hryniuk, Joseph Ragaz, William P. Peters
2004· letter· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
13
citations
affunlabeled
Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.
Erika Hamilton, Michelino De Laurentiis, Komal Jhaveri, Xichun Hu, Sylvain Ladoire, Anne Patsouris +14 more
2025· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
13
citations
affgemma · no categorygpt · no categorymodels agree
Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype.
Michael Gnant, Mitch Dowsett, Martin Filipits, Elena López‐Knowles, Richard Greil, Marija Balić +6 more
2013· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
13
citations
affunlabeled
Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).
Kim N., Neeraj Agarwal, Andrew J. Armstrong, Eva Hellmis, Friederike Schlürmann, Mikio Sugimoto +6 more
2024· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
13
citations

How this was built: Screen · Findings · About